Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses the effects of lowering DHT on hair loss and the importance of monitoring DHT levels during treatment. The user suggests that individual responses to DHT and hair loss treatments vary, and expresses a preference for topical treatments over oral medications due to concerns about systemic DHT reduction.

The conversation is about adjusting the dosage of topical Finasteride to avoid side effects like chest pain and breast swelling. The user is considering reducing the concentration to 0.1% or trying microdosing with 0.01-0.025% for lower systemic effects.

A user is considering exosome therapy from Springs Rejuvenation for hair loss after unsuccessful attempts with PRP, adipose injections, and a laser cap. They are intrigued by the therapy's potential and the clinic's guarantee of 30% improved coverage, despite concerns about FDA approval and high-pressure sales tactics.

Clascoterone 5% shows promising hair growth results but is criticized for high cost and unclear effectiveness compared to other treatments like finasteride. Glenmark is testing a combination of Clascoterone 7.5% and Minoxidil 5% in India.

The conversation is about the approval of Clascoterone (Winlevi) in Canada for hair loss treatment. One user expressed skepticism about its effectiveness due to low concentration.

A user is considering switching from finasteride to dutasteride due to unsatisfactory results and is concerned about experiencing another shedding phase. Another user recently made the switch and will update on their experience.

The user is considering stopping RU58841 due to inconvenience and potential side effects, while continuing with oral minoxidil and dutasteride. Another user shared their experience of stopping RU58841 without significant hair shedding while on dutasteride and minoxidil.

Finasteride and Dutasteride will remain accessible in the EU despite objections from France and Belgium. Users discuss the ease of obtaining these medications in different countries and express relief and support for the EU's decision.

The user shares their experience with a hair system, noting no one noticed the change except their girlfriend. They discuss the learning curve, maintenance tips, and their satisfaction with the results, feeling more confident and optimistic.

Procyanidin B2, a compound derived from Annurca apples, as a potential treatment for pattern hair loss. Several clinical studies were mentioned, which found that procyanidin B2 could increase hair growth, density, and keratin content. Other treatments such as Minoxidil, Finasteride, and RU58841 were not discussed.

A trichologist prescribed Biotrade Sebomax HR Anti-Hair Loss Tonic, Spectral DNC-N Nanoxidil, Hairfollic Him/Man Vitamins, and Bosley MD DHT blocking supplements instead of finasteride due to potential risks at age 21. The user questions the legitimacy of the treatment and considers seeking a second opinion.

FOL-005 claims to be more effective than Minoxidil and Finasteride but lacks anti-DHT properties, leading to potential reduced efficacy over time. Concerns are raised about misleading marketing and the safety of alternative treatments like Pyrilutamide and Clascoterone.

The conversation is about experimenting with topical exosomes for hair loss treatment, alongside microneedling, Happy Head's gel-like topical, and Ordinary's hair serum. The user also mentions the availability of treatments like latanoprost and Redensyl.

A user experienced side effects from hair loss treatment and contacted HIMS, resulting in their subscription being canceled. They were taking Zinc to manage symptoms and are considering consulting a doctor.

The user is documenting their experience with oral dutasteride (dut) 0.5 mg and minoxidil (min) 5 mg for hair loss, planning to add RU58841 after three months. They previously used finasteride with success and are now experiencing increased shedding but also new hair growth.

The conversation discusses buying RU58841 directly from a Chinese supplier for cost savings. It mentions that companies like Anageninc and Actifolic do the same.

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.

The conversation is about comparing hair loss treatments Pyrilutamide (KX-826) and CB-03-01, discussing their cost, side effects, and effectiveness. The user questions whether to try CB-03-01, which is more expensive and potentially less effective, or switch to the cheaper and possibly better Pyrilutamide.

The conversation discusses the best vehicle for topical dutasteride, comparing Trichosol, Transcutol, and a gel version. It also mentions using Transcutol with ethanol to enhance transdermal delivery of Bimatoprost.

Amplifica starting clinical trials for new hair loss drug. SCUBE3 protein discovered, stimulates hair growth, could be alternative to Minoxidil and Finasteride.

The conversation is about using Biolabshop's RU58841 product, which includes GHK-Cu and melatonin, to improve hair quality and combat hair loss. The user has previously used finasteride, minoxidil, and Anageninc’s RU58841 with success and seeks feedback on the new product, especially from those on anabolic steroids or hormone treatments.

The conversation discusses hair loss treatments, mentioning minoxidil, finasteride, RU58841, VDPHL, GT20029, and follicle cloning as potential solutions. It also reveals that the discussion about PP405 was an April Fool's joke.

The conversation discusses the effectiveness of adding RCP (redensyl, capixyl, procapil) to a hair loss treatment regimen that includes minoxidil and finasteride. Users share experiences, suggesting RCP may not be as effective as minoxidil, but could be useful for creating topical solutions.

The conversation is about whether to use gloves when applying 5% RU58841 to avoid systemic absorption and if washing hands with water is sufficient. Users question the concern, noting it is applied to the scalp.

KX-826 failed Phase III trials due to high placebo effects, patient compliance issues, COVID-19 side effects, and detection method deviations. KX-826 is now marketed as a cosmetic and approved for combination with Minoxidil.

The conversation discusses the anticipation of Chinese manufacturers producing Clascoterone 5% before its full approval in 2027. It also mentions treatments like Minoxidil, finasteride, and RU58841 for hair loss.

A user claims a product can treat alopecia, but others are skeptical, calling it a scam due to lack of evidence and transparency. The product is said to inhibit Type II 5-αr by 22.9%, but is considered weaker than existing DHT blockers.

Instagram accounts are misusing community hair progress pictures for marketing scams. Users suggest watermarking images to prevent misuse.

The conversation is about the safety of Breezula compared to RU58841 for hair loss treatment. The user believes Breezula is safer but less effective than RU58841.

The conversation is about the safety of using a dermastamp at 0.25mm depth twice a day when applying Minoxidil. The user seeks confirmation on whether this practice is safe despite mixed opinions.